copper peptide ghk cu skin clinical evidence review GHK-CU Before and After Pictures – Neurogan Health Frontiers | Exploring the beneficial

Huffman DM, Farias Quipildor G, Mao K, Zhang X, Wan J, Apontes P, Cohen P, Barzilai N

I use one needle to draw up and a new 26g 1 inch to IM inject

Full disclaimer 1.AOD-9604 is a 16-amino acid peptide fragment derived from human growth hormone (hGH residues 177-191) with added tyrosine, developed by Metabolic Pharmaceuticals for obesity treatment 2.Proposed mechanism: selective stimulation of lipolysis (fat breakdown) and inhibition of lipogenesis (fat formation) without growth hormone-like effects on IGF-1 or blood glucose 3.Failed Phase 2b clinical trial for obesity (2007)did not demonstrate statistically significant weight loss versus placebo, terminating clinical development for this indication 4.Received FDA "Generally Recognized as Safe" (GRAS) designation in 2023 as a food substance, but this is NOT a drug approval and does not establish efficacy for weight loss 5.Regulatory status: not FDA-approved as a drug, prohibited by WADA, and insufficient evidence for weight loss efficacy

Production of WFI is typically produced by distillation or reverse osmosis followed by ultrafiltration, to ensure the highest levels of purity

GHK-Cu is more recognized for its broader, systemic effects on skin integrity and overall anti-aging

The current evidence base therefore does not support conclusions regarding efficacy in postoperative recovery or complication reduction